Microba Life Sciences Ltd
ASX:MAP
Intrinsic Value
Microba Life Sciences is a precision microbiome science company powering medical innovation to transform human health. [ Read More ]
The intrinsic value of one MAP stock under the Base Case scenario is 0.24 AUD. Compared to the current market price of 0.16 AUD, Microba Life Sciences Ltd is Undervalued by 32%.
Valuation Backtest
Microba Life Sciences Ltd
Run backtest to discover the historical profit from buying and selling MAP stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Microba Life Sciences Ltd
| Current Assets | 42.5m |
| Cash & Short-Term Investments | 28.1m |
| Receivables | 11.3m |
| Other Current Assets | 3.2m |
| Non-Current Assets | 22.7m |
| PP&E | 3m |
| Intangibles | 19.7m |
| Current Liabilities | 13m |
| Accounts Payable | 7.2m |
| Accrued Liabilities | 610k |
| Short-Term Debt | 118.1k |
| Other Current Liabilities | 5.1m |
| Non-Current Liabilities | 3m |
| Long-Term Debt | 510.6k |
| Other Non-Current Liabilities | 2.5m |
Earnings Waterfall
Microba Life Sciences Ltd
|
Revenue
|
6.5m
AUD
|
|
Cost of Revenue
|
-3.5m
AUD
|
|
Gross Profit
|
3m
AUD
|
|
Operating Expenses
|
-36.4m
AUD
|
|
Operating Income
|
-33.3m
AUD
|
|
Other Expenses
|
14.9m
AUD
|
|
Net Income
|
-18.5m
AUD
|
Free Cash Flow Analysis
Microba Life Sciences Ltd
MAP Profitability Score
Profitability Due Diligence
Microba Life Sciences Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Microba Life Sciences Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
MAP Solvency Score
Solvency Due Diligence
Microba Life Sciences Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Microba Life Sciences Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MAP Price Targets Summary
Microba Life Sciences Ltd
According to Wall Street analysts, the average 1-year price target for MAP is 0.39 AUD with a low forecast of 0.35 AUD and a high forecast of 0.46 AUD.
Shareholder Return
MAP Price
Microba Life Sciences Ltd
| Average Annual Return | -10% |
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -69% |
| Market Capitalization | 71.7m AUD |
| Shares Outstanding | 447 851 977 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Microba Life Sciences is a precision microbiome science company powering medical innovation to transform human health. The company is headquartered in Brisbane, Queensland. The company went IPO on 2022-04-05. The firm specializes in the analysis of gut microbiome and promotes development in pathology services, therapeutics and diagnostics based on the microbiome. The firm's flagship product is the Microba Insight, a sampling kit that allows the public to analyze personal gut microbiome. Its discovery platform uses human data and informatic approaches to connect microbial genotype to human phenotype. The company also offers support solutions to researchers.
Contact
IPO
Employees
Officers
The intrinsic value of one MAP stock under the Base Case scenario is 0.24 AUD.
Compared to the current market price of 0.16 AUD, Microba Life Sciences Ltd is Undervalued by 32%.
You don't have any saved screeners yet
